Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 4 studies | 26% ± 7% | |
capillary endothelial cell | 3 studies | 17% ± 1% |
Insufficient scRNA-seq data for expression of CYP26B1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 99% | 3234.92 | 647 / 653 | 62% | 11.74 | 375 / 605 |
breast | 91% | 2819.34 | 416 / 459 | 60% | 3.96 | 670 / 1118 |
skin | 72% | 4073.46 | 1309 / 1809 | 75% | 6.51 | 352 / 472 |
kidney | 80% | 1451.24 | 71 / 89 | 65% | 4.45 | 590 / 901 |
uterus | 52% | 638.81 | 89 / 170 | 68% | 7.16 | 311 / 459 |
adrenal gland | 55% | 743.25 | 143 / 258 | 58% | 9.02 | 134 / 230 |
brain | 52% | 1727.33 | 1367 / 2642 | 60% | 6.07 | 425 / 705 |
esophagus | 31% | 309.15 | 454 / 1445 | 79% | 9.11 | 144 / 183 |
lung | 38% | 372.81 | 218 / 578 | 64% | 4.47 | 735 / 1155 |
adipose | 100% | 4655.75 | 1203 / 1204 | 0% | 0 | 0 / 0 |
ovary | 63% | 671.91 | 114 / 180 | 33% | 2.41 | 141 / 430 |
bladder | 52% | 475.76 | 11 / 21 | 36% | 4.87 | 183 / 504 |
eye | 0% | 0 | 0 / 0 | 88% | 10.28 | 70 / 80 |
intestine | 49% | 499.14 | 472 / 966 | 30% | 1.52 | 159 / 527 |
blood vessel | 73% | 980.89 | 981 / 1335 | 0% | 0 | 0 / 0 |
prostate | 40% | 426.47 | 98 / 245 | 33% | 1.41 | 167 / 502 |
lymph node | 0% | 0 | 0 / 0 | 72% | 5.87 | 21 / 29 |
tonsil | 0% | 0 | 0 / 0 | 71% | 6.96 | 32 / 45 |
spleen | 49% | 463.55 | 117 / 241 | 0% | 0 | 0 / 0 |
pancreas | 0% | 2.06 | 1 / 328 | 46% | 1.99 | 81 / 178 |
stomach | 4% | 57.66 | 15 / 359 | 40% | 2.38 | 115 / 286 |
heart | 42% | 633.47 | 362 / 861 | 0% | 0 | 0 / 0 |
muscle | 32% | 519.52 | 255 / 803 | 0% | 0 | 0 / 0 |
liver | 4% | 33.20 | 8 / 226 | 20% | 2.40 | 81 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0071300 | Biological process | cellular response to retinoic acid |
GO_0009954 | Biological process | proximal/distal pattern formation |
GO_0007283 | Biological process | spermatogenesis |
GO_0060349 | Biological process | bone morphogenesis |
GO_0006954 | Biological process | inflammatory response |
GO_0006766 | Biological process | vitamin metabolic process |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0045580 | Biological process | regulation of T cell differentiation |
GO_0070268 | Biological process | cornification |
GO_0043587 | Biological process | tongue morphogenesis |
GO_0001709 | Biological process | cell fate determination |
GO_0061436 | Biological process | establishment of skin barrier |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0001822 | Biological process | kidney development |
GO_0033189 | Biological process | response to vitamin A |
GO_0048387 | Biological process | negative regulation of retinoic acid receptor signaling pathway |
GO_0016125 | Biological process | sterol metabolic process |
GO_0042573 | Biological process | retinoic acid metabolic process |
GO_0001768 | Biological process | establishment of T cell polarity |
GO_0030326 | Biological process | embryonic limb morphogenesis |
GO_0034653 | Biological process | retinoic acid catabolic process |
GO_0048384 | Biological process | retinoic acid receptor signaling pathway |
GO_2001037 | Biological process | positive regulation of tongue muscle cell differentiation |
GO_0007140 | Biological process | male meiotic nuclear division |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0016709 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen |
GO_0062183 | Molecular function | all-trans retinoic acid 18-hydroxylase activity |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0008401 | Molecular function | retinoic acid 4-hydroxylase activity |
GO_0020037 | Molecular function | heme binding |
GO_0001972 | Molecular function | retinoic acid binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CYP26B1 |
Protein name | Cytochrome P450 26B1 Cytochrome P450 family 26 subfamily B member 1 Cytochrome P450 26B1 (EC 1.14.13.-) (Cytochrome P450 26A2) (Cytochrome P450 retinoic acid-inactivating 2) (Cytochrome P450RAI-2) (Retinoic acid-metabolizing cytochrome) |
Synonyms | CYP26A2 P450RAI2 |
Description | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active metabolites of vitamin A, and critical signaling molecules in animals . RAs exist as at least four different isomers: all-trans-RA (atRA), 9-cis-RA, 13-cis-RA, and 9,13-dicis-RA, where atRA is considered to be the biologically active isomer, although 9-cis-RA and 13-cis-RA also have activity (Probable). Catalyzes the hydroxylation of atRA primarily at C-4 and C-18, thereby contributing to the regulation of atRA homeostasis and signaling . Hydroxylation of atRA limits its biological activity and initiates a degradative process leading to its eventual elimination . Involved in the convertion of atRA to all-trans-4-oxo-RA. Can oxidize all-trans-13,14-dihydroretinoate (DRA) to metabolites which could include all-trans-4-oxo-DRA, all-trans-4-hydroxy-DRA, all-trans-5,8-epoxy-DRA, and all-trans-18-hydroxy-DRA (By similarity). Shows preference for the following substrates: atRA > 9-cis-RA > 13-cis-RA . Plays a central role in germ cell development: acts by degrading RAs in the developing testis, preventing STRA8 expression, thereby leading to delay of meiosis. Required for the maintenance of the undifferentiated state of male germ cells during embryonic development in Sertoli cells, inducing arrest in G0 phase of the cell cycle and preventing meiotic entry. Plays a role in skeletal development, both at the level of patterning and in the ossification of bone and the establishment of some synovial joints . Essential for postnatal survival (By similarity). .; FUNCTION: Has also a significant activity in oxidation of tazarotenic acid and may therefore metabolize that xenobiotic in vivo. . |
Accessions | ENST00000412253.1 Q9NR63 E7ER08 E5RHM2 ENST00000461519.1 ENST00000001146.7 [Q9NR63-1] E5RHN4 ENST00000474509.1 ENST00000546307.5 [Q9NR63-2] |